Top

Published in:

01-10-2019 | NSCLC | Research Paper

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Authors: Federico Carbone, Francesco Grossi, Aldo Bonaventura, Alessandra Vecchié, Silvia Minetti, Nicholas Bardi, Edoardo Elia, Anna Maria Ansaldo, Daniele Ferrara, Erika Rijavec, Maria Giovanna Dal Bello, Federica Biello, Giovanni Rossi, Marco Tagliamento, Angela Alama, Simona Coco, Paolo Spallarossa, Franco Dallegri, Carlo Genova, Fabrizio Montecucco

Published in: Clinical & Experimental Metastasis | Issue 5/2019

Abstract

Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.

Available only for authorised users

Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X (2019) Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19(1):558. https://doi.org/10.1186/s12885-019-5701-6 CrossRefPubMedPubMedCentral

Raju S, Joseph R, Sehgal S (2018) Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7:63–75. https://doi.org/10.2147/ITT.S125070 CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J (2017) PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200–215. https://doi.org/10.1016/j.lungcan.2017.08.005 CrossRefPubMed

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S (2018) Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 36(30):2995–3006. https://doi.org/10.1200/JCO.2018.78.1963 CrossRefPubMed

Glass NE, Rogovin D (1989) Transient electrodynamic response of thin-film superconductors to laser radiation. Phys Rev B Condens Matter 39(16):11327–11344CrossRefPubMed

Takeda T, Takeuchi M, Saitoh M, Takeda S (2018) Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. Thorac Cancer 9(10):1291–1299. https://doi.org/10.1111/1759-7714.12838 CrossRefPubMedPubMedCentral

Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, Basu A, Pennell N, Stevenson JP, Elson P, Panchabhai TS, Velcheti V (2018) Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE 13(10):e0197743. https://doi.org/10.1371/journal.pone.0197743 CrossRefPubMedPubMedCentral

10.

Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P (2018) Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist 23(8):936–942. https://doi.org/10.1634/theoncologist.2017-0452 CrossRefPubMedPubMedCentral

11.

Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081 CrossRefPubMedPubMedCentral

12.

Liu Y, Gu X, Lin Q, Tian T, Shao L, Yuan C, Zhang B, Fan K (2015) Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. Int J Clin Exp Med 8(8):12765–12773PubMedPubMedCentral

13.

Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ (2015) The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. Onco Targets Ther 8:3513–3521. https://doi.org/10.2147/OTT.S94082 CrossRefPubMedPubMedCentral

14.

Carbone F, Vuilleumier N, Burger F, Roversi G, Tamborino C, Casetta I, Seraceni S, Trentini A, Padroni M, Dallegri F, Mach F, Fainardi E, Montecucco F (2015) Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. Eur J Clin Invest 45(6):579–586. https://doi.org/10.1111/eci.12446 CrossRefPubMed

15.

Carbone F, Rigamonti F, Burger F, Roth A, Bertolotto M, Spinella G, Pane B, Palombo D, Pende A, Bonaventura A, Liberale L, Vecchie A, Dallegri F, Mach F, Montecucco F (2018) Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int J Cardiol 255:195–199. https://doi.org/10.1016/j.ijcard.2018.01.008 CrossRefPubMed

16.

Carbone F, Busto G, Padroni M, Bernardoni A, Colagrande S, Dallegri F, Montecucco F, Fainardi E (2018) Radiologic cerebral reperfusion at 24 h predicts good clinical outcome. Transl Stroke Res. https://doi.org/10.1007/s12975-018-0637-8 CrossRefPubMed

17.

Carbone F, Nulli Migliola E, Bonaventura A, Vecchie A, De Vuono S, Ricci MA, Vaudo G, Boni M, Dallegri F, Montecucco F, Lupattelli G (2018) High serum levels of C-reactive protein (CRP) predict beneficial decrease of visceral fat in obese females after sleeve gastrectomy. Nutr Metab Cardiovasc Dis 28(5):494–500. https://doi.org/10.1016/j.numecd.2018.01.014 CrossRefPubMed

18.

Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P (2011) Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 81(2):360–368. https://doi.org/10.1016/j.ijrobp.2010.06.011 CrossRefPubMed

19.

Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA (2018) The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer 18(1):310. https://doi.org/10.1186/s12885-018-4193-0 CrossRefPubMedPubMedCentral

20.

Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, Inaba Y, Takahashi K (2009) Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66(2):176–183. https://doi.org/10.1016/j.lungcan.2009.02.004 CrossRefPubMed

21.

Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN (2014) Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 19(3):742–748PubMed

22.

Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H (2017) Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway. Cancer Res 77(8):2018–2028. https://doi.org/10.1158/0008-5472.CAN-16-0808 CrossRefPubMedPubMedCentral

23.

Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X (2010) Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 67(1):114–119. https://doi.org/10.1016/j.lungcan.2009.03.017 CrossRefPubMed

24.

Liang Y, Li H, Hu B, Chen X, Miao JB, Li T, You B, Chen QR, Fu YL, Wang Y, Hou SC (2011) Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer. Chin J Cancer Res 23(1):64–68. https://doi.org/10.1007/s11670-011-0064-9 CrossRefPubMedPubMedCentral

25.

Chen Y, Liu H, Wu W, Li Y, Li J (2013) Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res 32:45. https://doi.org/10.1186/1756-9966-32-45 CrossRefPubMedPubMedCentral

26.

Han JC, Xu F, Du J, Zhang YJ, Wei YJ, Li HB, Li XD (2015) Serum osteopontin levels correlate with clinical and pathological features in non-small cell lung cancer. Anal Quant Cytopathol Histpathol 37(5):295–301PubMed

27.

Karadag F, Gulen ST, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, Cildag O (2011) Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest 71(8):690–694. https://doi.org/10.3109/00365513.2011.621549 CrossRefPubMed

28.

Hao Y, Liu J, Wang P, Wang F, Yu Z, Li M, Chen S, Ning F (2014) OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC. Int J Genomics 2014:846142. https://doi.org/10.1155/2014/846142 CrossRefPubMedPubMedCentral

29.

Shi L, Wang X (2017) Role of osteopontin in lung cancer evolution and heterogeneity. Semin Cell Dev Biol 64:40–47. https://doi.org/10.1016/j.semcdb.2016.08.032 CrossRefPubMed

30.

Singh R, Hui T, Matsui A, Allahem Z, Johnston CD, Ruiz-Torruella M, Rittling SR (2017) Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin. Immunology 150(1):74–86. https://doi.org/10.1111/imm.12668 CrossRefPubMed

31.

Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ, Sodek J (2011) Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132(1):39–48. https://doi.org/10.1111/j.1365-2567.2010.03335.x CrossRefPubMedPubMedCentral

32.

Eruslanov EB (2017) Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer. Cancer Immunol Immunother 66(8):997–1006. https://doi.org/10.1007/s00262-017-1976-0 CrossRefPubMedPubMedCentral

33.

Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A (2017) Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017:4049098. https://doi.org/10.1155/2017/4049098 CrossRefPubMedPubMedCentral

Title: Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer
Authors: Federico Carbone
Francesco Grossi
Aldo Bonaventura
Alessandra Vecchié
Silvia Minetti
Nicholas Bardi
Edoardo Elia
Anna Maria Ansaldo
Daniele Ferrara
Erika Rijavec
Maria Giovanna Dal Bello
Federica Biello
Giovanni Rossi
Marco Tagliamento
Angela Alama
Simona Coco
Paolo Spallarossa
Franco Dallegri
Carlo Genova
Fabrizio Montecucco
Publication date: 01-10-2019
Publisher: Springer Netherlands
Keywords: NSCLC
NSCLC
Published in: Clinical & Experimental Metastasis / Issue 5/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-09984-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study

The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis

Factors related to the quality of life in patients with bone metastases

Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer